Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Up 959.3% in February

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a significant increase in short interest in February. As of February 13th, there was short interest totaling 157,037 shares, an increase of 959.3% from the January 29th total of 14,825 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 1,130,051 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 1,130,051 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.1% of the company’s shares are short sold.

Oncotelic Therapeutics Stock Performance

OTCMKTS:OTLC traded up $0.00 during trading hours on Friday, hitting $0.05. The company had a trading volume of 79,844 shares, compared to its average volume of 267,996. The stock has a 50-day moving average price of $0.07 and a 200 day moving average price of $0.08. Oncotelic Therapeutics has a 52 week low of $0.02 and a 52 week high of $0.11.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.